Enterprise Value

0.00

Cash

52.2M

Avg Qtr Burn

N/A

Short % of Float

8.04%

Insider Ownership

4.10%

Institutional Own.

88.47%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bardoxolone Methyl Details
Chronic kidney disease, Alport Syndrome

Failed

Discontinued

Bardoxolone Methyl Details
Autosomal Dominant Polycystic Kidney Disease, Chronic kidney disease

Failed

Discontinued

Bardoxolone Methyl Details
Focal segmental glomerulosclerosis

Failed

Discontinued

Bardoxolone Methyl Details
IgA nephropathy, Chronic kidney disease

Failed

Discontinued

Bardoxolone Methyl Details
Type 1 diabetes, Chronic kidney disease

Failed

Discontinued